Trading Report: The Supernus Pharmaceuticals Inc. (SUPN) Lifted to Buy at Zacks Investment Research

The Supernus Pharmaceuticals Inc. (SUPN) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) from a hold rating to a buy rating in a report issued on Wednesday morning. The firm currently has $26.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

A number of other research analysts also recently weighed in on SUPN. Jefferies Group restated a buy rating and issued a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Northland Securities downgraded Supernus Pharmaceuticals from an outperform rating to a market perform rating and set a $24.00 price target for the company. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. downgraded Supernus Pharmaceuticals from an overweight rating to a neutral rating and set a $23.00 price target for the company. in a research note on Monday, July 18th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of Buy and a consensus target price of $25.25.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 23.78 on Wednesday. The firm has a 50-day moving average price of $23.52 and a 200-day moving average price of $20.05. The company has a market capitalization of $1.18 billion, a PE ratio of 48.53 and a beta of 1.73. Supernus Pharmaceuticals has a 12 month low of $9.51 and a 12 month high of $26.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.05. The firm earned $50.40 million during the quarter, compared to the consensus estimate of $49.67 million. Supernus Pharmaceuticals had a return on equity of 20.99% and a net margin of 14.94%. The business’s revenue was up 43.6% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share. On average, equities research analysts predict that Supernus Pharmaceuticals will post $0.68 EPS for the current year.

In other news, CFO Gregory S. Patrick sold 3,395 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total transaction of $74,690.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Gregory S. Patrick sold 2,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 16th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares of the company’s stock, valued at $90,400. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in SUPN. BlackRock Fund Advisors boosted its stake in Supernus Pharmaceuticals by 1.1% in the first quarter. BlackRock Fund Advisors now owns 2,826,989 shares of the specialty pharmaceutical company’s stock valued at $43,112,000 after buying an additional 31,238 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in Supernus Pharmaceuticals by 1.3% in the second quarter. Rice Hall James & Associates LLC now owns 543,606 shares of the specialty pharmaceutical company’s stock valued at $11,073,000 after buying an additional 7,161 shares during the last quarter. Alps Advisors Inc. boosted its stake in Supernus Pharmaceuticals by 26.2% in the second quarter. Alps Advisors Inc. now owns 69,426 shares of the specialty pharmaceutical company’s stock valued at $1,414,000 after buying an additional 14,407 shares during the last quarter. California State Teachers Retirement System boosted its stake in Supernus Pharmaceuticals by 35.2% in the second quarter. California State Teachers Retirement System now owns 98,380 shares of the specialty pharmaceutical company’s stock valued at $2,004,000 after buying an additional 25,597 shares during the last quarter. Finally, Nicholas Investment Partners LP purchased a new stake in Supernus Pharmaceuticals during the first quarter valued at $1,990,000. 94.66% of the stock is owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Related posts

Leave a Comment